Uphononongo oluPhucukileyo olupapashwe kwiGazi: Unyango lwe-CD7 CAR-T olusekwe kwi-Nanobody lwe-Acute Myeloid Leukemia
Iqela lezonyango laseLu Daopei lenze inkqubela ephawulekayo kwicandelo le-hematology. Phantsi kobunkokeli bukaGqr. Lu Peihua, uphando lwabo oluphambili, "I-Nanobody-based Naturally Selected CD7-Targeted Chimeric Antigen Iseli ye-Receptor T Unyango lwe-Acute Myeloid Leukemia”, ipapashwe kutshanje kwijenali edumileyo kwihlabathi liphela Igazi (Impembelelo: 21). Olu phando lubonisa indlela entsha yokunyanga i-acute myeloid leukemia (AML), ebonisa ukusebenza kakuhle kunye nokhuseleko olubalaseleyo lokubulala ithumba ngelixa libonelela ngethemba elitsha kwizigulana ezine-relapse okanye i-refractory (R/R) AML.
Indlela entsha
Olu phononongo luqalise ukusetyenziswa kweeseli ze-CD7 CAR-T ezisekelwe kwi-nanobody kunyango lwe-AML. Unyango lwendabuko lwe-CAR-T ludla ngokusebenzisa iziqwenga eziguquguqukayo ze-single-chain (scFv) ezivela kwi-monoclonal antibodies (mAbs). Olu phando lusebenzise ii-nanobodies—ii-antibodies ze-single-domain ezivela kwi-camelid heavy-chain antibodies. Ii-nanobodies, ngenxa yobukhulu bazo obuncinci (15kDa xa kuthelekiswa ne-150kDa human IgG) kunye nokunciphisa i-immunogenicity, zibonelela nge-antigen specific ephezulu kunye ne-binding affinity ngelixa zinciphisa iziphumo ebezingalindelekanga.
I-NS7CAR-T esekelwe kwi-nanobody ibonise ukusebenza kakuhle kunye nokhuseleko oluphuculweyo lokulwa nethumba kwizilingo zangaphambi kweklinikhi kunye nezeklinikhi. Iziphumo zangaphambi kweklinikhi zibonise ukwanda okuphezulu kweeseli kunye nomsebenzi wokulwa nethumba xa kuthelekiswa neeseli ze-CAR-T ezisekelwe kwi-scFv. Ngaphezu koko, kwisilingo seklinikhi seSigaba soku-1, unyango lufikelele kwizinga lokuxolelwa ngokupheleleyo le-70% phakathi kwezigulane ezili-10 ezine-CD7-positive AML, kunye ne-60% efikelele kwisimo esincinci sesifo esisele (MRD).
Impembelelo yeKlinikhi
Uvavanyo lubhalise izigulane ezineeprofayili ezinobungozi obukhulu, kuquka ezo zazikhe zafakelwa iiseli ze-hematopoietic stem cell ngaphambili (allo-HSCT) okanye iindlela ezininzi zonyango. Nangona le mingeni, unyango lwe-NS7CAR-T olusekelwe kwi-nanobody lufumene iziphumo ezithembisayo ezinemiphumo emibi elawulekayo, kuquka ne-mild cytokine release syndrome (CRS) kwi-80% yabathathi-nxaxheba. Akukho matyala e-neurotoxicity abonweyo.
Izikhokelo Zexesha Elizayo
Olu phononongo lugxininisa imfuneko yezilingo ezinkulu ukuqinisekisa ukusebenza kakuhle kunye nokhuseleko lonyango lwe-CD7 CAR-T olusekelwe kwi-nanobody kunyango lwe-AML. Lukwagxininisa imingeni efana nokulahleka kwe-CD7 antigen, okuhlala kungumqobo omkhulu kwiimeko zokubuyela umva. Ukujongana nale miba kuya kuba ngundoqo ekwenzeni ngcono unyango kwizicelo ezininzi zeklinikhi.
I-Horizon entsha yoNyango lwe-AML
I-AML, isifo segazi esinzima kakhulu nesingafaniyo, sele sidala imingeni ekufezekiseni uxolelo oluhlala ixesha elide kunye nokuphucula amazinga okusinda ngokubanzi. Olu tshintsho luqaliswe yiLu Daopei Medical Team aluboneleli nje kuphela ngendlela entsha yonyango kwizigulane kodwa lukwaqinisa ukuvelela kwazo kwezemfundo kuphando lwe-hematology lwehlabathi.
Olu phawu lubalulekileyo lusebenza njengobungqina bokuzinikela kweqela ekudibaniseni uphando oluphambili kunye nokusebenza kwezonyango. Njengoko iqela liqhubeka nokuphonononga unyango oluphambili, umsebenzi wabo uzisa ithemba elitsha kwizigulane kwihlabathi liphela kwaye uvula indlela yokuqhubela phambili okuguquguqukayo kwi-hematology.